|
|
The value of epigenetic markers in esophageal
cancer |
Xiao-Mei ZHANG,Ming-Zhou GUO, |
Department of Gastroenterology
& Hepatology, Chinese PLA General Hospital, Beijing 100853, China; |
|
|
Abstract Developing esophageal cancer is a multi-step process that begins with the accumulation of genetic and epigenetic alterations, and leads to the activation of oncogenes and the inactivation or loss of tumor suppressor genes (TSG). In addition to genetic alteration, epigenetic modifications, and in particular DNA methylation, are recognized as a common molecular alteration in human tumors. In esophageal cancer, aberrant methylation of promoter regions occurs not only in advanced cancer, but also in premalignant lesions. DNA methylation is related to survival time and sensitivity of chemoradiotherapy. This review is mainly focused on epigenetic changes in esophageal cancer and the value of early detection for patient prognosis, treatment choices, and potential targeting therapy.
|
Keywords
epigenetics
DNA methylation
esophageal cancer
dysplasia
|
Issue Date: 05 December 2010
|
|
|
Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin, 2005, 55(2): 74―108 PMID: 15761078
|
|
Hu N, Dawsey S M, Wu M, Bonney G E, He L J, Han X Y, Fu M, Taylor P R. Family history of oesophageal cancer in Shanxi Province. Int J Epidemiol, 1992, 21(5): 877―822 PMID: 1468848
|
|
Yang C S. Research on esophageal cancer in China: a review.Cancer Res, 1980, 40(8 Pt 1): 2633―2644 PMID: 6992989
|
|
Taylor P R, Dawsey S M, Hu N, Albanes D, Wu M. Nutritional interventionto prevent hereditary cancer.J Natl CancerInst Monogr, 1995, (17): 43―47 PMID: 8573452
|
|
Carter C L, Hu N, Wu M, Lin P Z, Murigande C, Bonney G E. Segregation analysis of esophageal cancer in 221 high-risk Chinesefamilies.J Natl Cancer Inst, 1992, 84(10): 771―776 PMID: 1573663
|
|
Mu?oz N. Epidemiological aspects of oesophageal cancer.Endoscopy, 1993, 25(9): 609―612 PMID: 8119215
|
|
Nielsen N H, Mikkelsen F, Hansen J P. Oesophageal cancer in Greenland:selected epidemiological and clinical aspects.J Cancer Res Clin Oncol, 1979, 94(1): 69―80 PMID: 381317
|
|
Cameron A J. Epidemiology of columnar-lined esophagus and adenocarcinoma.Gastroenterol Clin North Am, 1997, 26(3): 487―494 PMID: 9309399
|
|
Okano J, Snyder L, Rustgi A K. Genetic alterations in esophageal cancer.Methods Mol Biol, 2003, 222: 131―145 PMID: 12710684
|
|
Vogelstein B, Kinzler K W. The multistep nature of cancer.TrendsGenet, 1993, 9(4): 138―141 PMID: 8516849
|
|
Zhang W, Gl?ckner S C, Guo M, Machida E O, Wang D H, Easwaran H, Van Neste L, Herman J G, Schuebel K E, Watkins D N, Ahuja N, Baylin S B. Epigenetic inactivation of the canonical Wnt antagonistSRY-box containing gene 17 in colorectal cancer.Cancer Res, 2008, 68(8): 2764―2772 PMID: 18413743
|
|
Wang J S, Guo M, Montgomery E A, Thompson R E, Cosby H, Hicks L, Wang S, Herman J G, Canto M I. DNA promoter hypermethylation of p16 and APC predictsneoplastic progression in Barrett's esophagus.Am J Gastroenterol, 2009, 104(9): 2153―2160 PMID: 19584833
|
|
Carmona F J, Esteller M. Epigenomics of human colon cancer. MutatRes, 2010, 693(1―2):53―60 PMID: 20691710
|
|
Mokrowiecka A, Wierzchniewska-?awska A, Smolarz B, Romanowicz-Makowska H, Malecka-Panas E. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence]. Pol Merkur Lekarski, 2009, 26(155): 385―389 PMID: 19606680
|
|
Kohler E M, Brauburger K, Behrens J, Schneikert J. Contribution of the 15 amino acid repeats of truncatedAPC to beta-catenin degradation and selection of APC mutations incolorectal tumours from FAP patients.Oncogene, 2010, 29(11): 1663―1671 PMID: 19966865
|
|
Holliday R. The inheritance of epigenetic defects.Science, 1987, 238(4824): 163―170 PMID: 3310230
|
|
Jones P A, Baylin S B. The fundamentalrole of epigenetic events in cancer.NatRev Genet, 2002, 3(6): 415―428 PMID: 12042769
|
|
Riggs A D, Pfeifer G P. X-chromosome inactivation and cell memory.Trends Genet, 1992, 8(5): 169―174 PMID: 1369742
|
|
Ali A B, Iau P T, Sng J H. Cancer-specific methylation in the BRCA1promoter in sporadic breast tumours. MedOncol, 2010Feb5. DOI: 10.1007/S12032-010-9438-Y
doi: 10.1007/S12032-010-9438-Y
|
|
Merlo A, Herman J G, Mao L, Lee D J, Gabrielson E, Burger P C, Baylin S B, Sidransky D. 5′ CpG island methylation is associatedwith transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1in human cancers.Nat Med, 1995, 1(7): 686―692 PMID: 7585152
|
|
Guo M, House M G, Suzuki H, Ye Y, Brock M V, Lu F, Liu Z, Rustgi A K, Herman J G. Epigenetic silencing of CDX2 is a feature of squamous esophagealcancer.Int J Cancer, 2007, 121(6): 1219―1226 PMID: 17534889
|
|
Guo M, House M G, Akiyama Y, Qi Y, Capagna D, Harmon J, Baylin S B, Brock M V, Herman J G. Hypermethylation of the GATA gene family in esophageal cancer.Int J Cancer, 2006, 119(9): 2078―2083 PMID: 16823849
|
|
Aguilera O, Fraga M F, Ballestar E, Paz M F, Herranz M, Espada J, García J M, Mu?oz A, Esteller M, González-Sancho J M. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1)gene in human colorectal cancer.Oncogene, 2006, 25(29): 4116―4121 PMID: 16491118
|
|
Martinez R, Setien F, Voelter C, Casado S, Quesada M P, Schackert G, Esteller M. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8is a common hallmark of relapsed glioblastoma multiforme.Carcinogenesis, 2007, 28(6): 1264―1268 PMID: 17272309
|
|
Blanco D, Vicent S, Fraga M F, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, Lecanda F, Montuenga L M. Molecular analysis of a multisteplung cancer model induced by chronic inflammation reveals epigeneticregulation of p16 and activation of the DNA damage response pathway.Neoplasia, 2007, 9(10): 840―852 PMID: 17971904
|
|
Yue W, Sun Q, Dacic S, Landreneau R J, Siegfried J M, Yu J, Zhang L. Downregulationof Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer.Carcinogenesis, 2008, 29(1): 84―92 PMID: 18048388
|
|
Lee B B, Lee E J, Jung E H, Chun H K, Chang D K, Song S Y, Park J, Kim D H. Aberrant methylation of APC, MGMT, RASSF2A,and Wif-1 genes in plasma as a biomarker for early detection of colorectalcancer.Clin Cancer Res, 2009, 15(19): 6185―6191 PMID: 19773381
|
|
Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, Song X, Lesche R, Liebenberg V, Ebert M, Molnar B, Grützmann R, Pilarsky C, Sledziewski A. DNA methylation biomarkers for blood-based colorectalcancer screening.Clin Chem, 2008, 54(2): 414―423 PMID: 18089654
|
|
Atherfold P A, Jankowski J A. Molecular biology of Barrett's cancer.Best Pract Res Clin Gastroenterol, 2006, 20(5): 813―827 PMID: 16997163
|
|
Dulai G S, Guha S, Kahn K L, Gornbein J, Weinstein W M. Preoperative prevalence ofBarrett's esophagus in esophageal adenocarcinoma: a systematicreview.Gastroenterology, 2002, 122(1): 26―33 PMID: 11781277
|
|
Corley D A, Levin T R, Habel L A, Weiss N S, Buffler P A. Surveillance and survivalin Barrett's adenocarcinomas: a population-based study.Gastroenterology, 2002, 122(3): 633―640 PMID: 11874995
|
|
McManus D T, Olaru A, Meltzer S J. Biomarkers of esophageal adenocarcinomaand Barrett's esophagus.Cancer Res, 2004, 64(5): 1561―1569 PMID: 14996709
|
|
Bian Y S, Osterheld M C, Fontolliet C, Bosman F T, Benhattar J. p16 inactivation by methylation of the CDKN2A promoter occurs earlyduring neoplastic progression in Barrett's esophagus.Gastroenterology, 2002, 122(4): 1113―1121 PMID: 11910361
|
|
Wong D J, Paulson T G, Prevo L J, Galipeau P C, Longton G, Blount P L, Reid B J. p16(INK4a) lesions are common, early abnormalities thatundergo clonal expansion in Barrett's metaplastic epithelium.Cancer Res, 2001, 61(22): 8284―8289 PMID: 11719461
|
|
Klump B, Hsieh C J, Holzmann K, Gregor M, Porschen R. Hypermethylation of the CDKN2/p16promoter during neoplastic progression in Barrett's esophagus.Gastroenterology, 1998, 115(6): 1381―1386 PMID: 9834265
|
|
Wong D J, Barrett M T, St?ger R, Emond M J, Reid B J. p16INK4apromoter is hypermethylated at a high frequency in esophageal adenocarcinomas.Cancer Res, 1997, 57(13): 2619―2622 PMID: 9205067
|
|
Eads C A, Lord R V, Wickramasinghe K, Long T I, Kurumboor S K, Bernstein L, Peters J H, DeMeester S R, DeMeester T R, Skinner K A, Laird P W. Epigeneticpatterns in the progression of esophageal adenocarcinoma.Cancer Res, 2001, 61(8): 3410―3418 PMID: 11309301
|
|
Guo M, Ren J, House M G, Qi Y, Brock M V, Herman J G. Accumulation of promoter methylation suggests epigeneticprogression in squamous cell carcinoma of the esophagus.Clin Cancer Res, 2006, 12(15): 4515―4522 PMID: 16899597
|
|
Guo M, Ren J, Brock M V, Herman J G, Carraway H E. Promoter methylation of HIN-1in the progression to esophageal squamous cancer.Epigenetics, 2008, 3(6): 336―341 PMID: 19098448
|
|
Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton J P, David S, Agarwal R, Selaru F M, Sato F, Abraham J M, Beer D G, Mori Y, Shimada Y, Meltzer S J. Promoter hypermethylationof CDH13 is a common, early event in human esophageal adenocarcinogenesisand correlates with clinical risk factors.Int J Cancer, 2008, 123(10): 2331―2336 PMID: 18729198
|
|
Jin Z, Hamilton J P, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Beer D G, Agarwal R, Abraham J M, Meltzer S J. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associatedesophageal neoplastic progression.CancerEpidemiol Biomarkers Prev, 2008, 17(1): 111―117 PMID: 18199717
|
|
Jin Z, Mori Y, Hamilton J P, Olaru A, Sato F, Yang J, Ito T, Kan T, Agarwal R, Meltzer S J. Hypermethylation of the somatostatin promoter is a common, earlyevent in human esophageal carcinogenesis.Cancer, 2008, 112(1): 43―49 PMID: 17999418
|
|
Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, Mori Y, Mantzur C, Paun B, Hamilton J P, Ito T, Wang S, David S, Agarwal R, Beer D G, Abraham J M, Meltzer S J. Hypermethylation of tachykinin-1 is a potential biomarker in humanesophageal cancer.Clin Cancer Res, 2007, 13(21): 6293―6300 PMID: 17975140
|
|
Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton J P, Kan T, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Hypermethylation of the nel-like1 gene is a common and early event and is associated with poor prognosisin early-stage esophageal adenocarcinoma.Oncogene, 2007, 26(43): 6332―6340 PMID: 17452981
|
|
Kuester D, Dar A A, Moskaluk C C, Krueger S, Meyer F, Hartig R, Stolte M, Malfertheiner P, Lippert H, Roessner A, El-Rifai W, Schneider-Stock R. Early involvement of death-associatedprotein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association withclinical progression.Neoplasia, 2007, 9(3): 236―245 PMID: 17401463
|
|
Hamilton J P, Sato F, Jin Z, Greenwald B D, Ito T, Mori Y, Paun B C, Kan T, Cheng Y, Wang S, Yang J, Abraham J M, Meltzer S J. Reprimo methylation is apotential biomarker of Barrett's-Associated esophageal neoplasticprogression.Clin Cancer Res, 2006, 12(22): 6637―6642 PMID: 17121882
|
|
Anupam K, Tusharkant C, Gupta S D, Ranju R. Loss of disabled-2 expression is an early event in esophagealsquamous tumorigenesis.World J Gastroenterol, 2006, 12(37): 6041―6045 PMID: 17009406
|
|
Clément G, Braunschweig R, Pasquier N, Bosman F T, Benhattar J. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation.J Pathol, 2006, 208(1): 100―107 PMID: 16278815
|
|
Zou H, Osborn N K, Harrington J J, Klatt K K, Molina J R, Burgart L J, Ahlquist D A. Frequent methylation of eyes absent 4 gene in Barrett's esophagusand esophageal adenocarcinoma.Cancer EpidemiolBiomarkers Prev, 2005, 14(4): 830―834 PMID: 15824152
|
|
Campbell N P, Villaflor V M. Neoadjuvant treatment of esophageal cancer.World J Gastroenterol, 2010, 16(30): 3793―3803 PMID: 20698042
|
|
Hyngstrom J R, Posner M C. Neoadjuvantstrategies for the treatment of locally advanced esophageal cancer.J Surg Oncol, 2010, 101(4): 299―304 PMID: 20187065
|
|
Kim M P, Correa A M, Lee J, Rice D C, Roth J A, Mehran R J, Walsh G L, Ajani J A, Maru D M, Chang J Y, Marom E M, Macapinlac H A, Lee J H, Vaporciyan A A, Rice T, Swisher S G, Hofstetter W L. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery:an orphan status.Ann Thorac Surg, 2010, 90(3): 884―890, discussion 890―891 PMID: 20732513
|
|
Metzger R, Heukamp L, Drebber U, Bollschweiler E, Zander T, Hoelscher A H, Warnecke-Eberz U. CUL2 and STK11 as novel response-predictivegenes for neoadjuvant radiochemotherapy in esophageal cancer.Pharmacogenomics, 2010, 11(8): 1105―1113 PMID: 20712528
|
|
Esteller M, Garcia-Foncillas J, Andion E, Goodman S N, Hidalgo O F, Vanaclocha V, Baylin S B, Herman J G. Inactivationof the DNA-repair gene MGMT and the clinical response of gliomas toalkylating agents.N Engl J Med, 2000, 343(19): 1350―1354 PMID: 11070098
|
|
Rivera A L, Pelloski C E, Gilbert M R, Colman H, De La Cruz C, Sulman E P, Bekele B N, Aldape K D. MGMT promotermethylation is predictive of response to radiotherapy and prognosticin the absence of adjuvant alkylating chemotherapy for glioblastoma.Neuro Oncol, 2010, 12(2): 116―121 PMID: 20150378
|
|
Hamilton J P, Sato F, Jin Z, Greenwald B D, Ito T, Mori Y, Paun B C, Kan T, Cheng Y, Wang S, Yang J, Abraham J M, Meltzer S J. Reprimo methylation is apotential biomarker of Barrett's-Associated esophageal neoplasticprogression.Clin Cancer Res, 2006, 12(22): 6637―6642 PMID: 17121882
|
|
Hamilton J P, Sato F, Greenwald B D, Suntharalingam M, Krasna M J, Edelman M J, Doyle A, Berki A T, Abraham J M, Mori Y, Kan T, Mantzur C, Paun B, Wang S, Ito T, Jin Z, Meltzer S J. Promoter methylation and response to chemotherapy andradiation in esophageal cancer.Clin GastroenterolHepatol, 2006, 4(6): 701―708 PMID: 16678495
|
|
Mandelker D L, Yamashita K, Tokumaru Y, Mimori K, Howard D L, Tanaka Y, Carvalho A L, Jiang W W, Park H L, Kim M S, Osada M, Mori M, Sidransky D. PGP9.5 promoter methylationis an independent prognostic factor for esophageal squamous cell carcinoma.Cancer Res, 2005, 65(11): 4963―4968 PMID: 15930319
|
|
Li L W, Yu X Y, Yang Y, Zhang C P, Guo L P, Lu S H. Expression of esophageal cancer related gene 4 (ECRG4),a novel tumor suppressor gene, in esophageal cancer and its inhibitoryeffect on the tumor growth in vitro and in vivo.Int J Cancer, 2009, 125(7): 1505―1513 PMID: 19521989
|
|
Brock M V, Gou M, Akiyama Y, Muller A, Wu T T, Montgomery E, Deasel M, Germonpré P, Rubinson L, Heitmiller R F, Yang S C, Forastiere A A, Baylin S B, Herman J G. Prognostic importance of promoter hypermethylationof multiple genes in esophageal adenocarcinoma.Clin Cancer Res, 2003, 9(8): 2912―2919 PMID: 12912936
|
|
Kawakami K, Brabender J, Lord R V, Groshen S, Greenwald B D, Krasna M J, Yin J, Fleisher A S, Abraham J M, Beer D G, Sidransky D, Huss H T, Demeester T R, Eads C, Laird P W, Ilson D H, Kelsen D P, Harpole D, Moore M B, Danenberg K D, Danenberg P V, Meltzer S J. Hypermethylated APC DNA in plasma and prognosis of patients withesophageal adenocarcinoma.J Natl CancerInst, 2000, 92(22): 1805―1811 PMID: 11078757
|
|
Lee E J, Lee B B, Kim J W, Shim Y M, Hoseok I, Han J, Cho E Y, Park J, Kim D H. Aberrant methylation of Fragile Histidine Triad gene is associatedwith poor prognosis in early stage esophageal squamous cell carcinoma.Eur J Cancer, 2006, 42(7): 972―980 PMID: 16564166
|
|
Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton J P, Kan T, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Hypermethylation of the nel-like1 gene is a common and early event and is associated with poor prognosisin early-stage esophageal adenocarcinoma. Oncogene, 2007, 26(43): 6332―6340
|
|
Ohta M, Mimori K, Fukuyoshi Y, Kita Y, Motoyama K, Yamashita K, Ishii H, Inoue H, Mori M, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Clinical significance ofthe reduced expression of G protein gamma 7 (GNG7) in oesophagealcancer.Br J Cancer, 2008, 98(2): 410―417 PMID: 18219292
|
|
Lee E J, Lee B B, Han J, Cho E Y, Shim Y M, Park J, Kim D H. CpG islandhypermethylation of E-cadherin (CDH1) and integrin alpha4 is associatedwith recurrence of early stage esophageal squamous cell carcinoma.Int J Cancer, 2008, 123(9): 2073―2079 PMID: 18697202
|
|
Zare M, Jazii F R, Alivand M R, Nasseri N K, Malekzadeh R, Yazdanbod M. Qualitative analysis of Adenomatous Polyposis Coli promoter:hypermethylation, engagement and effects on survival of patients withesophageal cancer in a high risk region of the world, a potentialmolecular marker.BMC Cancer, 2009, 9: 24 PMID: 19149902
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|